The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesIP: Use at 5-15µg/mg of lysate.
WB: 1/2000 - 1/10000. Predicted molecular weight: 82 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionRegulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Binds to activated (phosphorylated) protein-tyrosine kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Indirectly regulates autophagy (PubMed:23604317). Promotes nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement.
Involvement in diseaseMegalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1
Sequence similaritiesBelongs to the PI3K p85 subunit family. Contains 1 Rho-GAP domain. Contains 2 SH2 domains. Contains 1 SH3 domain.
DomainThe SH2 2 domain is required for interaction with FBXL2 and PTPN13.
Post-translational modificationsPhosphorylated in response to signaling from activated receptor-type protein kinases (PubMed:19690332, PubMed:20068231). Dephosphorylated by PTPRJ (PubMed:18348712). Dephosphorylated at Tyr-655 by PTPN13. Phosphorylation of Tyr-655 impairs while its dephosphorylation promotes interaction with FBXL2 and SCF(FBXL2)-mediated polyubiquitination (PubMed:23604317). Ubiquitinated. Polyubiquitination by the SCF(FBXL2) complex probably promotes proteasomal degradation of PIK3R2.
Western blot - PI 3 Kinase p85 beta antibody (ab93778)
All lanes : Anti-PI 3 Kinase p85 beta antibody (ab93778) at 0.04 µg/ml
Lane 1 : Hela cell lysate at 50 µg Lane 2 : Hela cell lysate at 15 µg Lane 3 : HeLa cell lysate at 5 µg
Developed using the ECL technique
Predicted band size : 82 kDa
Exposure time : 30 seconds
Immunoprecipitation - PI 3 Kinase p85 beta antibody (ab93778)
Immunoprecipitation : 1 mg of HeLa cell lysate immunoprecipitated with antibody at 10 µg/mg lysate; 20% of immunoprecipitate loaded in each lane All lanes : PI 3 Kinase p85 beta antibody (ab93778) at 1 µg/ml Lane 1 : Lysate immunoprecipitated with ab93778 Lane 2 : Lysate immunoprecipitated with a control IgG Predicted band size : 82 kDa
Developed using the ECL technique Exposure time : 10 seconds
References for Anti-PI 3 Kinase p85 beta antibody (ab93778)
has not yet been referenced specifically in any publications.
Publishing research using ab93778? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"